News Release
“Gu Bang” receives approval from the Chinese SFDA for sales in China
- Title :”Gu Bang” receives approval from the Chinese SFDA for sales in China
- Date :Mar 6, 2006
- Location :Shanghai, China
- Description :The first therapeutic product of GNI and Shanghai Genomics, “GuBang” synthetic bone graft, receives approval from the Chinese SFDA for sales in China. A complete value chain from gene research to production and sales has been formed for the Company in Shanghai.